<sup>1</sup>Universities Space Research Association, <sup>2</sup>U of Tokushima Graduate School of Medicine, <sup>3</sup>Baylor College of Medicine, <sup>4</sup> Kennedy Krieger Institute, <sup>5</sup>UCSF, <sup>6</sup>NASA Johnson Space Center, <sup>7</sup>Wyle Science, Technology and Engineering Group, <sup>8</sup>U of California at Irvine, <sup>9</sup>U of Occupational and Environmental Health, <sup>10</sup>Nagoya City U, <sup>11</sup>JAXA, <sup>12</sup>U of N Texas Health Science Center

# Statement of Problem: What do we know from the supporting data?

- Bone loss: ISS (Table 1, Fig. 1); Skylab (single photon absorptiometry, Ca balance); Mir (DXA)
- Elevated bone resorption markers: ISS (Fig. 2); Skylab; multiple bed rest studies
- Elevated urinary Ca: ISS (Fig. 4); Skylab; multiple bed rest studies
- Uncoupled remodeling: ISS (Figs. 2,3); multiple bed rest studies

## Table 1. QCT vBMD and FE Strength Changes

Pre-ARED (Low Resis Ex) vs ARED (High Resis Ex) vs ARED + Alendronate, R + < 2 weeks


QCT BMD (g/cm3)	Pre-ARED Control (n=18) % Change	ARED Control (n=8) %Change	Alendrona ARED (n=7) %Change
Total Hip		1	
Trabecular	$-13.6 \pm 6.4^{1}$	$-7.6 \pm 6.0^{1}$	$-1.1 \pm 9.8^{-1}$
Cortical	-3.2 ± 3.5	-2.6 ± 1.8	-0.6 ± 4.7
Trochanter			
Trabecular	$-13.5 \pm 6.5^{1}$	- <b>7.2 ± 6.6</b> <sup>1</sup>	-1.9 ± 9.9 <sup>2</sup>
Cortical	-3.2 ± 3.3 <sup>1</sup>	-3.3 ± 2.7 <sup>1</sup>	-0.5 ± 5.0
Femoral Neck			
Trabecular	$-15.0 \pm 9.8^{1}$	-15.7 ± 17.8 <sup>1</sup>	6.5 ± 14.8
Cortical	-4.0 ± 5.5	-1.8 ± 2.8	-1.0 ± 4.8
Finite Element Strength (N)			
Non-Linear Stance	-9.5 ± 5.6 <sup>1</sup>	1.7 ± 7.9	1.9 ± 9.7
Non-Linear Fall	-14.1 ± 8.1 <sup>1</sup>	-2.7 ± 5.8	0.8 ± 10.
$1 \mathbf{D}_{\mathbf{r} \mathbf{o}}$ , $\mathbf{D}_{\mathbf{o} \mathbf{o}} \mathbf{c} \mathbf{t} = \mathbf{D}_{\mathbf{o} \mathbf{o}} \mathbf{c} \mathbf{t}$			

<sup>1</sup>Pre vs. Post, P < 0.05</li>
 <sup>2</sup>ARED + Alendronate vs. Pre-ARED, P < 0.05</li>
 <sup>3</sup>ARED + Alendronate vs. ARED, P < 0.05</li>

# Spaceflight Bone Atrophy: Problem Solved?

Adrian LeBlanc<sup>1</sup>, Toshio Matsumoto<sup>2</sup>, Jeffrey Jones<sup>3</sup>, Jay Shapiro<sup>4</sup>, Thomas Lang<sup>5</sup>, Linda Shackelford<sup>6</sup>, Scott M. Smith<sup>6</sup>, Harlan Evans<sup>7</sup>, Elisabeth Spector<sup>7</sup>, Robert Ploutz-Snyder<sup>1</sup>, Jean Sibonga<sup>6</sup>, Joyce Keyak<sup>8</sup>, Toshitaka Nakamura<sup>9</sup>, Kenjiro Kohri<sup>10</sup>, Hiroshi Ohshima<sup>11,</sup> Gilbert Moralez <sup>12</sup>

on absorptiometry, Ca balance); Mir (DXA) ylab; multiple bed rest studies bed rest studies ed rest studies




Pre-ARED (Low Resis Ex) vs ARED (High Resis Ex) vs ARED+Alendronate, R<2 Weeks


Fig. 1 DXA BMD Changes

7<sup>2</sup>).1<sup>2</sup>

1Pre vs. Post, P < 0.05 2ARED + Alendronate vs. Pre-ARED, P < 0.05 3ARED + Alendronate vs. ARED, P < 0.05</pre>




#### **Fig. 3 BSAP Changes** Pre-ARED (Low Resis Ex) vs ARED (High Resis Ex) vs ARED+Alendronate



\*Significant Diff. vs. Pre-Flight, P < 0.05, with Bonferroni correction (based on absolute data) Pre ARED and ARED data calculated from Smith paper 2012 JBMR


#### Fig. 4 Urinary Ca Changes

#### Pre-ARED (Low Resis Ex) vs ARED (High Resis Ex) vs ARED+Alendronate



\*Significant Diff. vs. Pre-Flight, P < 0.05, with Bonferroni correction Pre ARED data calculated from Smith Paper 2012 JBMR





National Aeronautics and Space Administration

## **Conclusions**

- 1) From a flight risk standpoint, the problem is considered manageable
- Data show that exercise plus an anti-resorptive will be effective, reducing bone loss, bone resorption and urinary Ca excretion (lowering renal stone risk)
- 3) Targeted high resistive exercise alone can significantly attenuate bone loss but not necessarily completely

## **Potential Research Areas**

## General

- 1) What are the molecular biology details for bone loss in space?
- 2) Related to the above, what is the explanation for the large variability in response between individuals and bone sites?

## **Topics Related to Resistive Exercise Use in Space**

Why do resorption markers remain elevated while improving bone homeostasis?

- 1) Why do formation and resorption markers appear to remain essentially uncoupled? Do bone markers represent regional metabolic conditions?
- 2) Is there a compartmental redistribution of bone with targeted high resistive exercise?
- 3) How can in-flight resistive exercise be made more efficient/efficacious?
- 4) Does resistive exercise impact frequency and severity of inflight injuries and ways to prevent?

## **Topics Related to Pharmaceutical Use in Space**

- 1) Drug stability for long missions
- 2) Operational plan needed, e.g., in cases of equipment failure or crew injury where exercise may not be possible
- 3) Suitability of other anti-resorptives (e.g., cathepsin K, Rank-L inhibitors)
- 4) Suitability of anabolic drugs